Quarterly report pursuant to Section 13 or 15(d)

Business Acquisition - Schedule of Revenue and Net Loss Attributable to Acquisition (Details)

v3.19.2
Business Acquisition - Schedule of Revenue and Net Loss Attributable to Acquisition (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Revenues $ 2,431,721 $ 2,441,007 $ 3,755,961 $ 5,343,804
Net loss attributable to H-CYTE (5,297,271) $ (362,722) (8,992,087) $ (1,259,922)
Medovex Corp [Member]        
Revenues   35,505  
Net loss attributable to H-CYTE $ (894,585)   $ (1,948,962)